TGFB1 and myelodysplastic syndrome: Elritercept (KER-050), a novel inhibitor of TGF-β signaling, achieved durable transfusion independence in IPSS-R very low-, low-, or intermediate-risk MDS patients according to its Phase 2 results [154].